Rapid, direct, and qualitative method for the determination of the number of HIV-1-infected patient cells employing reactive oxygen intermediate generators
US5667964A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Oct 28, 1994 |
| Grant date | Sep 16, 1997 |
| Priority date | — |
| Expiry date | Oct 28, 2014 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/56988
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The ability to monitor the progression of human immunodeficiency virus (HIV) infection in patients is paramount to the study of HIV transmission, in predicting the onset and advancement of disease, and evaluating the clinical efficacy of therapeutics. Present methods available to the clinician for the study of HIV pathogenesis employ surrogate markers. Surrogate markers are biological indicators that tend to reflect, to varying extent, the gradual progression of the asymptomatic state to the development of acquired immune deficiency syndrome (AIDS). The most commonly used markers are CD4.sup.+ lymphocyte counts and HIV p24 antigen production. The use of markers to evaluate disease progression suffers from a number of limitations. No known marker consistently reflects disease progression in all patients and stages of disease. Moreover, an effective marker must rapidly reflect the changes associated with antiviral therapy. Accordingly, there still exists in the field a need for a rapid and direct technique for assessing the viral load of an HIV-infected patient. The present invention discloses a rapid method for qualitatively determining the number of HIV-1-infected patient cells in …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.